Cargando…

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?

Detalles Bibliográficos
Autores principales:	Al Sharie, Ahmed H., Abu Mousa, Balqis M., Alomari, Ahmad O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Academy for Clinical Hematology (IACH) 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515879/ https://www.ncbi.nlm.nih.gov/pubmed/37752987 http://dx.doi.org/10.46989/001c.87501

Ejemplares similares

Treatment of Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Where Do We Stand? Where Do We Go?
por: Eichenauer, Dennis A., et al.
Publicado: (2023)

COVID-19 Vaccine in Children: Where Do We Stand?
por: Kumar, Jogender, et al.
Publicado: (2021)

Topical Pramoxine in Chronic Pruritus: Where do We Stand?
por: Agarwal, Akash, et al.
Publicado: (2021)

Monkeypox virus crosstalk with HIV; where do we stand now?
por: Shafaati, Maryam, et al.
Publicado: (2022)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?
por: Mehta, Puja, et al.
Publicado: (2020)

Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma
por: Abuelgasim, Khadega A., et al.
Publicado: (2019)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
por: Van Den Neste, Eric, et al.
Publicado: (2018)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Genetics of Keratoconus: Where Do We Stand?
por: Abu-Amero, Khaled K., et al.
Publicado: (2014)

Clofarabine in Pediatric Acute Relapsed or Refractory Leukemia: Where Do We Stand on the Bridge to Hematopoietic Stem Cell Transplantation?
por: Ramiz, Sarah, et al.
Publicado: (2023)

Where Do We Stand?
Publicado: (1891)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Enigma of Extrapulmonary Tuberculosis: Where Do We Stand?
por: Inayat, Faisal, et al.
Publicado: (2017)

Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?
por: Mei, Matthew G., et al.
Publicado: (2023)

The need for pediatric indoor physical training guidelines during COVID-19 pandemic–related lockdown: where do we stand?
por: Arun Babu, Thirunavukkarasu
Publicado: (2022)

Gravity: where do we stand ?
por: Peron, Roberto, et al.
Publicado: (2016)

Addictive behaviors: where do we stand, and where are we going?
por: Thibaut, Florence, et al.
Publicado: (2017)

Transoral Incisionless Fundoplication for Refractory Gastroesophageal Reflux Disease: Where Do We Stand?
por: Jain, Deepanshu, et al.
Publicado: (2016)

Tailoring treatment for MALT lymphoma patients: where do we stand now?
por: Johnson, Peter W., et al.
Publicado: (2017)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma
por: Mata, Elena, et al.
Publicado: (2019)

ColVI myopathies: where do we stand, where do we go?
por: Allamand, Valérie, et al.
Publicado: (2011)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Biomarkers for Alzheimer’s Disease: Where Do We Stand and Where Are We Going?
por: Villa, Chiara
Publicado: (2020)

We Stand Corrected
por: Zoepfl, Fred J.
Publicado: (1995)

Pixel Detectors ... where do we stand?
por: Wermes, Norbert
Publicado: (2019)

Laser accelerators : where do we stand
por: Lawson, J D
Publicado: (1985)

Renormalization schemes: where do we stand?
por: Ward, B F L
Publicado: (1990)

Barrett's Esophagus: Where Do We Stand?
por: Al Madi, Majid A.
Publicado: (2009)

Maximizing neuroprotection: where do we stand?
por: Kuffler, Damien P
Publicado: (2012)

LHC Access - Where do we Stand
por: Ninin, P, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_rfdf691tfcu4mtd2gdompja101